drugset
drugset / Trial / NCT06369727

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369727 ↗

Phase 1 Completed 250 enrolled Moberg Pharma AB
RandomizedParallel-groupOpen-labelOther

Summary

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential

Timeline

Start
2017-10-15
Primary completion
2018-02-15
Completion
2018-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject MOB015B Unknown — Topical

Indications

No indication recorded.